Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.
Fuchs JD, Sobieszczyk ME, Madenwald T, Grove D, Karuna ST, Andrasik M, Sherwat A, Broder G, Mayer K, Koblin B, Hammer S; HVTN 505 Protocol Team. Fuchs JD, et al. Among authors: sobieszczyk me. J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):259-62. doi: 10.1097/QAI.0b013e318296df94. J Acquir Immune Defic Syndr. 2013. PMID: 23614998 Free PMC article. Clinical Trial.
Correlates of psychological distress among undergraduate women engaged in remote learning through a New York City college during the COVID-19 pandemic.
Heck CJ, Theodore DA, Sovic B, Austin E, Yang C, Rotbert J, Greissman S, Zucker J, Autry A, Catallozzi M, Sobieszczyk ME, Castor D. Heck CJ, et al. Among authors: sobieszczyk me. J Am Coll Health. 2023 Jan 17:1-10. doi: 10.1080/07448481.2022.2156797. Online ahead of print. J Am Coll Health. 2023. PMID: 36649543
Back2PrEP: Rates of Bacterial Sexually Transmitted Infection Diagnosis Among Individuals Returning to HIV Pre-Exposure Prophylaxis Care: A Retrospective Review of a New York City Comprehensive HIV Prevention Program.
McLean J, Bartram L, Zucker J, LaSota E, Carnevale C, Richards P, Perez E, Mori K, Mgbako O, Olender S, Cohall A, Gordon P, Sobieszczyk M. McLean J, et al. AIDS Patient Care STDS. 2022 Dec;36(12):458-461. doi: 10.1089/apc.2022.0169. Epub 2022 Nov 16. AIDS Patient Care STDS. 2022. PMID: 36383140 Free PMC article.
AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection.
Aksyuk AA, Bansal H, Wilkins D, Stanley AM, Sproule S, Maaske J, Sanikommui S, Hartman WR, Sobieszczyk ME, Falsey AR, Kelly EJ. Aksyuk AA, et al. Among authors: sobieszczyk me. Cell Rep Med. 2023 Jan 17;4(1):100882. doi: 10.1016/j.xcrm.2022.100882. Epub 2022 Dec 15. Cell Rep Med. 2023. PMID: 36610390 Free PMC article.
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation.
Wang Q, Li Z, Ho J, Guo Y, Yeh AY, Mohri H, Liu M, Wang M, Yu J, Shah JG, Chang JY, Herbas F, Yin MT, Sobieszczyk ME, Sheng Z, Liu L, Ho DD. Wang Q, et al. Among authors: sobieszczyk me. Lancet Infect Dis. 2022 Dec;22(12):1666-1668. doi: 10.1016/S1473-3099(22)00694-6. Epub 2022 Oct 31. Lancet Infect Dis. 2022. PMID: 36328002 Free PMC article. No abstract available.
Advances in antiretroviral therapy.
Sobieszczyk ME, Talley AK, Wilkin T, Hammer SM. Sobieszczyk ME, et al. Top HIV Med. 2005 Mar-Apr;13(1):24-44. Top HIV Med. 2005. PMID: 15849370
Advances in antiretroviral therapy.
Sobieszczyk ME, Jones J, Wilkin T, Hammer SM. Sobieszczyk ME, et al. Top HIV Med. 2006 Mar-Apr;14(1):36-62. Top HIV Med. 2006. PMID: 16641526
The challenge of HIV-1 subtype diversity.
Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. Taylor BS, et al. Among authors: sobieszczyk me. N Engl J Med. 2008 Apr 10;358(15):1590-602. doi: 10.1056/NEJMra0706737. N Engl J Med. 2008. PMID: 18403767 Free PMC article. Review. No abstract available.
129 results